Cargando…

The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder

OBJECTIVE: The prevalence and clinically associated factors of hyperuricemia (HUA) have been widely studied in the general population but rarely in patients with bipolar disorder (BPD) co-morbid with HUA. This study attempted to investigate the prevalence of HUA in BPD patients and analyze the assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuyun, Lu, Xiaobing, Chen, Xiaodong, Huang, Zebin, Zhou, Hui, Li, Zezhi, Ning, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523783/
https://www.ncbi.nlm.nih.gov/pubmed/36188459
http://dx.doi.org/10.3389/fnins.2022.998747
_version_ 1784800362173038592
author Li, Shuyun
Lu, Xiaobing
Chen, Xiaodong
Huang, Zebin
Zhou, Hui
Li, Zezhi
Ning, Yuping
author_facet Li, Shuyun
Lu, Xiaobing
Chen, Xiaodong
Huang, Zebin
Zhou, Hui
Li, Zezhi
Ning, Yuping
author_sort Li, Shuyun
collection PubMed
description OBJECTIVE: The prevalence and clinically associated factors of hyperuricemia (HUA) have been widely studied in the general population but rarely in patients with bipolar disorder (BPD) co-morbid with HUA. This study attempted to investigate the prevalence of HUA in BPD patients and analyze the associated correlates of HUA. MATERIALS AND METHODS: In this study, 182 outpatients with BPD and 182 healthy controls participated. The demographic and clinical information were collected. The body weight, height, waist circumference (WC), hip circumference (HC), and blood pressure (BP) were measured. The levels of serum uric acid (UA), triglyceride (TG), high-density lipoprotein (HDL-C), and fasting blood glucose (FBG) were also determined. RESULTS: BPD patients had a significantly higher prevalence of HUA (40.7%) compared to healthy controls (30.2%) (χ(2) = 4.335, P = 0.037). The systolic blood pressure (SBP), pulse pressure (PP), FBG, UA, and body mass index (BMI) were higher in the BPD group compared with those in the control group, while the diastolic blood pressure (DBP) and HDL-C level were lower (P < 0.05) in BPD patients. The prevalence of HUA was higher in BPD patients who used antipsychotics combined with mood stabilizers than that in BPD subjects receiving the mood stabilizers alone (P < 0.001). The prevalence of HUA and increased serum UA levels were higher in the manic group (62.1%) than in the depressive (34.3%) or euthymia group (17.0%) (P < 0.001). Additionally, the severity of mania was positively correlated with the UA level (r = 0.410, P < 0.001). There were significant differences in terms of MetS (29.7% vs. 14.8%), BMI, HC, WC, TG, and HDL-C between the HUA and the non-HUA groups (P < 0.05). The unconditional logistic regression analysis revealed that high BMI (OR = 1.210; 95%CI: 1.100–1.331) and high TG level (OR = 1.652; 95%CI: 1.058–2.580) were the major risk factorids for HUA in BPD patients. CONCLUSION: Our study suggests that patients with BPD are prone to metabolic diseases such as HUA. Higher serum levels of TG and high BMI could be associated with HUA development. Clinicians need to regularly monitor and evaluate BPD patients for their serum UA levels, especially for BPD patients with manic/hypomanic episodes and/or under the treatment of antipsychotics combined with mood stabilizers.
format Online
Article
Text
id pubmed-9523783
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95237832022-10-01 The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder Li, Shuyun Lu, Xiaobing Chen, Xiaodong Huang, Zebin Zhou, Hui Li, Zezhi Ning, Yuping Front Neurosci Neuroscience OBJECTIVE: The prevalence and clinically associated factors of hyperuricemia (HUA) have been widely studied in the general population but rarely in patients with bipolar disorder (BPD) co-morbid with HUA. This study attempted to investigate the prevalence of HUA in BPD patients and analyze the associated correlates of HUA. MATERIALS AND METHODS: In this study, 182 outpatients with BPD and 182 healthy controls participated. The demographic and clinical information were collected. The body weight, height, waist circumference (WC), hip circumference (HC), and blood pressure (BP) were measured. The levels of serum uric acid (UA), triglyceride (TG), high-density lipoprotein (HDL-C), and fasting blood glucose (FBG) were also determined. RESULTS: BPD patients had a significantly higher prevalence of HUA (40.7%) compared to healthy controls (30.2%) (χ(2) = 4.335, P = 0.037). The systolic blood pressure (SBP), pulse pressure (PP), FBG, UA, and body mass index (BMI) were higher in the BPD group compared with those in the control group, while the diastolic blood pressure (DBP) and HDL-C level were lower (P < 0.05) in BPD patients. The prevalence of HUA was higher in BPD patients who used antipsychotics combined with mood stabilizers than that in BPD subjects receiving the mood stabilizers alone (P < 0.001). The prevalence of HUA and increased serum UA levels were higher in the manic group (62.1%) than in the depressive (34.3%) or euthymia group (17.0%) (P < 0.001). Additionally, the severity of mania was positively correlated with the UA level (r = 0.410, P < 0.001). There were significant differences in terms of MetS (29.7% vs. 14.8%), BMI, HC, WC, TG, and HDL-C between the HUA and the non-HUA groups (P < 0.05). The unconditional logistic regression analysis revealed that high BMI (OR = 1.210; 95%CI: 1.100–1.331) and high TG level (OR = 1.652; 95%CI: 1.058–2.580) were the major risk factorids for HUA in BPD patients. CONCLUSION: Our study suggests that patients with BPD are prone to metabolic diseases such as HUA. Higher serum levels of TG and high BMI could be associated with HUA development. Clinicians need to regularly monitor and evaluate BPD patients for their serum UA levels, especially for BPD patients with manic/hypomanic episodes and/or under the treatment of antipsychotics combined with mood stabilizers. Frontiers Media S.A. 2022-09-16 /pmc/articles/PMC9523783/ /pubmed/36188459 http://dx.doi.org/10.3389/fnins.2022.998747 Text en Copyright © 2022 Li, Lu, Chen, Huang, Zhou, Li and Ning. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Li, Shuyun
Lu, Xiaobing
Chen, Xiaodong
Huang, Zebin
Zhou, Hui
Li, Zezhi
Ning, Yuping
The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder
title The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder
title_full The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder
title_fullStr The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder
title_full_unstemmed The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder
title_short The prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder
title_sort prevalence and associated clinical correlates of hyperuricemia in patients with bipolar disorder
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523783/
https://www.ncbi.nlm.nih.gov/pubmed/36188459
http://dx.doi.org/10.3389/fnins.2022.998747
work_keys_str_mv AT lishuyun theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT luxiaobing theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT chenxiaodong theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT huangzebin theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT zhouhui theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT lizezhi theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT ningyuping theprevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT lishuyun prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT luxiaobing prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT chenxiaodong prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT huangzebin prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT zhouhui prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT lizezhi prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder
AT ningyuping prevalenceandassociatedclinicalcorrelatesofhyperuricemiainpatientswithbipolardisorder